Basic and clinical studies on ritipenem acoxil in urinary tract infection

We studied the antibacterial activity and clinical efficacy of ritipenem acoxil (RIPM-AC), a neworal penem antibiotic, in urinary tract infections. 1) Antibacterial activity: We measured the MICs of ritipenem (RIPM) against 210 clinicalisolates of 14 species from urinary tract infections and compared them with those of cefaclor (CCL), cefixime (CFIX) and cefotiam (CTM). Against gram-positive organisms, the overallantibacterial activity of RIPM was superior to that of other antibiotics. Against gram-negativeorganisms, the activity of RIPM was almost equivalent to that of other antibiotics. 2) Clinical efficacy: Four patients with acute uncomplicated cystitis (AUC) and 30 patients withchronic complicated urinary tract infection were treated with ritipenem acoxil. According to thecriteria of the Japanese UTI Committee, the overall clinical efficacy rate was 100%(2/2) for AUC and 85.7%(24/28) for chronic complicated UTI. Bacteriologically, 28 of 32 strains (87.5%) wereeradicated. 3) Side effects: No side effects were observed. Abnormal laboratory findings, however, wereobserved in 2 cases, one with slight elevations of GOT and GPT and the other with decreases in RBC, Hb and Ht.